RWM
SGMT icon

Rialto Wealth Management’s Sagimet Biosciences SGMT Stock Holding History

Rialto Wealth Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88K Hold
359
– – ﹤0.01% 884
2025
Q4 		$2.13K Hold
359
– – ﹤0.01% 725
2025
Q3 		$2.46K Hold
359
– – ﹤0.01% 615
2025
Q2 		$2.74K Buy
+359
New +$1.51K ﹤0.01% 546

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rialto Wealth Management's SGMT Position: Q1 2026 in Review

Rialto Wealth Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 359 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Rialto Wealth Management first reported a position in SGMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.74K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Rialto Wealth Management held 359 shares of Sagimet Biosciences worth $1.88K as of Q1 2026.
  • Rialto Wealth Management left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #884 holding.
  • Rialto Wealth Management first reported a position in Sagimet Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Rialto Wealth Management's Sagimet Biosciences position peaked at $2.74K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.